Evidence map›Paper›PMID 23265555›Full record

ReviewPathogens and global health2012

Current status and future perspectives on the medical treatment of neurocysticercosis.

Isidro Gonzales, Hector H Garcia

Abstract readReview
In one paragraph

Review in Pathogens and global health, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Use of Ivermectin in Neurocysticercosis: A Case Report.The American journal of case reports · 2018
    Review
  6. Pediatric neurocysticercosis: current challenges and future prospects.Pediatric health, medicine and therapeutics · 2016
    Review
  7. Managing neurocysticercosis: challenges and solutions.International journal of general medicine · 2015
    Review
  8. Article
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Isidro GonzalesInstituto Nacional de Ciencias Neurologicas, Lima, Peru.
Hector H Garcia
Instituto Nacional de Ciencias NeurológicasUniversidad Peruana Cayetano Heredia · PE

Funding

Training in Parasitic Diseases and Central Nervous System Infections in Peru.D43TW001140 · FIC · UNIVERSIDAD PERUANA CAYETANO HEREDIA · PI GARCIA, HECTOR HUGO, GILMAN, ROBERT H · 1999 to 2025
$5.7M
FIC NIH HHS D43 TW001140Wellcome Trust 091077
6 · The paper itself

Abstract

Neurological disease resulting from neurocysticercosis (NCC) is common in most of the world. The variability in the biology of the infection and in its clinical manifestations has led to much confusion regarding appropriate management. Therapeutic options have evolved from surgery, symptomatic measures, and steroids, to include the use of anti-parasitic drugs and minimally invasive neurosurgery. This manuscript reviews the principles of medical therapy for NCC, from discussion of the need for individualized management approaches for each type of NCC to exploration of the most likely potential additions or modifications currently under study.

Indexed as

AnthelminticsHumansNeurocysticercosisNeurosurgical ProceduresAnthelmintics

Identifiers

PMID23265555
PMCPMC4005114
OpenAlexW2085577073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.